Updated
Migraine: Asian pipelines and global competitors
As of 2026-11-14, Asian migraine assets include Brise’s pivotal-stage BR005, two undisclosed preclinical programs partnered by Brise and AbbVie, and Atzumi, the intranasal dihydroergotamine product from SNBL-owned Satsuma. Global comparators include atogepant, eptinezumab and rimegepant. Acute and preventive treatment are separated; a preclinical partnership is not evidence of efficacy in people.
Brise’s two unnamed programs are grouped in one collaboration record without invented codes. Satsuma is US-based and controlled by a Japanese parent.
Asian companies
| Asset | Company | Mechanism / route | Stage | Indication | Deal / rights | Latest verified record | Sources |
|---|---|---|---|---|---|---|---|
BR005 | Brise (China) | Oral small molecule; target not disclosed in cited release Oral | Pivotal clinical trials; phase not specified in cited release | Acute migraine treatment in adults | No verified deal terms identified | The 11-02 issuer release lists BR005 in pivotal trials; it is separate from the 2 preclinical programs partnered with AbbVie. | |
Two undisclosed preclinical programs | Brise (China) / AbbVie | Targets not publicly disclosed in cited release Not disclosed | Preclinical | Migraine; specific settings not disclosed | Agreement entered in 2024; updated in 2026; unverified amounts omitted | The 11-02 update concerns an agreement entered in 2024: Brise leads discovery and AbbVie global development and commercialization; it is not a new 2026 agreement. | |
STS101 / Atzumi (dihydroergotamine) | Satsuma / SNBL (Japanese parent) | Ergot derivative; serotonergic receptor activity Intranasal powder | Approved in the US; 2025-04 | Acute migraine treatment in adults | No verified deal terms identified | The company lists 2026-06 AHS abstracts and 2025-04 FDA approval; this does not establish commercial launch. |
Global comparators
| Asset | Company | Mechanism / route | Stage | Indication | Latest verified record | Sources |
|---|---|---|---|---|---|---|
atogepant / Qulipta / Aquipta | AbbVie | CGRP receptor antagonist Oral | Approved product; Phase 3 menstrual-migraine results | Migraine prevention; separate menstrual-migraine population | Reported Phase 3 LUNA met its primary and eight ranked secondary endpoints; results are not approval for menstrual migraine. | |
eptinezumab / Vyepti | Lundbeck | Anti-CGRP antibody IV | Approved in Japan | Prevention of migraine attacks in adults | Announced Japanese MHLW marketing authorization for prevention of migraine attacks in adults. | |
rimegepant / Nurtec ODT | Pfizer | CGRP receptor antagonist Orally disintegrating tablet | Approved in the US | Acute migraine / prevention of episodic migraine in adults | The cited US label is revised 2026-04; no later dated product event was verified in this review. |
Events in the last 90 days
2026-08-17 – 2026-11-14
BR005
The 11-02 issuer release lists BR005 in pivotal trials; it is separate from the 2 preclinical programs partnered with AbbVie. Primary source
Two undisclosed preclinical programs
The 11-02 update concerns an agreement entered in 2024: Brise leads discovery and AbbVie global development and commercialization; it is not a new 2026 agreement. Primary source
eptinezumab / Vyepti
Announced Japanese MHLW marketing authorization for prevention of migraine attacks in adults. Primary source
atogepant / Qulipta / Aquipta
Reported Phase 3 LUNA met its primary and eight ranked secondary endpoints; results are not approval for menstrual migraine. Primary source
Sources and downloads
- Brise issuer release via PRNewswire — 2026-11-02
- Satsuma issuer release archive — 2026-06
- AbbVie LUNA topline results — 2026-09-10
- Lundbeck issuer release via Cision — 2026-09-16
- Pfizer Nurtec ODT US label — 2026-04
Information cutoff 2026-11-14